<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-150042</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Current diagnosis and treatment of Castleman's disease</dc:title>
<dc:description xml:lang="en">Castleman's disease is not just a single disease but rather an uncommon, heterogeneous group of nonclonal lymphoproliferative disorders, which have a broad spectrum of clinical expression. Three histological types have been reported, along with several clinical forms according to clinical presentation, histological substrate and associated diseases. Interleukin-6, its receptor polymorphisms, the human immunodeficiency virus and the human herpes virus 8 are involved in the etiopathogenesis of Castleman's disease. The study of this disease has shed light on a syndrome whose incidence is unknown. Despite recent significant advances in our understanding of this disease and the increasing therapeutic experience with rituximab, tocilizumab and siltuximab, there are still difficult questions concerning its aetiology, prognosis and optimal treatment (AU)</dc:description>
<dc:creator>Patier de la Peña, JL</dc:creator>
<dc:creator>Moreno Cobo, MA</dc:creator>
<dc:creator>González García, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La enfermedad de Castleman no es una única enfermedad. Bajo este epónimo se reúne un heterogéneo grupo de trastornos linfoproliferativos no clonales, muy infrecuentes, con un amplio espectro de expresión clínica. Se han descrito 3 tipos histológicos, junto con varias formas clínicas, según la forma de presentación, el sustrato histológico y las enfermedades asociadas. La interleucina 6, los polimorfismos del receptor de esta interleucina, el virus de la inmunodeficiencia humana y el virus herpes humano tipo 8 están implicados en la etiopatogenia y su estudio ha aportado luz al conocimiento de un síndrome cuya incidencia es desconocida. A pesar de avances recientes e importantes en su conocimiento y de la progresiva experiencia terapéutica con rituximab, tocilizumab y siltuximab, aún existen preguntas difíciles de contestar con los factores etiológicos, el abordaje terapéutico óptimo y el pronóstico (AU)</dc:description>
<dc:source>Rev Clin Esp;216(3): 146-156, abr. 2016. tab, ilus</dc:source>
<dc:identifier>ibc-150042</dc:identifier>
<dc:title xml:lang="es">Diagnóstico y tratamiento actual de la enfermedad de Castleman</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d29411^s22016</dc:subject>
<dc:subject>^d11812</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d922</dc:subject>
<dc:subject>^d29411^s22032</dc:subject>
<dc:subject>^d1002^s22073</dc:subject>
<dc:subject>^d29411^s22012</dc:subject>
<dc:subject>^d29411^s22067</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d29411^s22011</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d32898^s22021</dc:subject>
<dc:subject>^d32898^s22038</dc:subject>
<dc:subject>^d29411^s22080</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201604</dc:date>
</metadata>
</record>
</ibecs-document>
